Drug Profile
PDL1 t haNK - ImmunityBio
Alternative Names: PD-L1 T-haNK; PD-L1 targeted high-affinity natural killer cells - ImmunityBio; PD-L1.t-haNK; t-haNK™ Cells; t‑haNK®Latest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator NantKwest
- Developer ImmunityBio
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Gastric cancer; Pancreatic cancer; Squamous cell cancer
- No development reported Non-small cell lung cancer; Solid tumours
Most Recent Events
- 25 Sep 2023 ImmunityBio plans a phase II trial for Glioblastoma(Recurrent, Second-line therapy or greater, Combination therapy) in November 2023 (IV) (NCT06061809)
- 19 Jan 2023 Updated efficacy data from a phase II QUILT-88 trial in Pancreatic cancer released by ImmunityBio
- 28 Sep 2022 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy) in USA (Parenteral)